Fudan-Zhangjiang Schedules 14 August 2026 Board Meeting to Review 1H26 Unaudited Results

Bulletin Express

Yesterday

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (Fudan-Zhangjiang) has announced that its board of directors will convene on 14 August 2026 to review and approve the unaudited interim financial results for the six months ended 30 June 2026.

The board currently comprises eight members: • Executive Directors: Zhao Da Jun (Chairman) and Xue Yan • Non-executive Directors: Zhong Tao and Yu Xiao Yang • Independent Non-executive Directors: Wang Hong Guang, Lam Siu Wing and Xu Pei Long • Employee Director: Qu Ya Nan

The notice was released in Shanghai on 31 July 2026. No additional agenda items or financial figures were disclosed in the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173180583"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173180583\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173180583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173180583","market":"us","top_or_hot":-1,"title":"Fudan-Zhangjiang Schedules 14 August 2026 Board Meeting to Review 1H26 Unaudited Results","media":"Bulletin Express","content":"<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (Fudan-Zhangjiang) has announced that its board of directors will convene on 14 August 2026 to review and approve the unaudited interim financial results for the six months ended 30 June 2026.</p>\n<p>The board currently comprises eight members:\n• Executive Directors: Zhao Da Jun (Chairman) and Xue Yan  \n• Non-executive Directors: Zhong Tao and Yu Xiao Yang  \n• Independent Non-executive Directors: Wang Hong Guang, Lam Siu Wing and Xu Pei Long  \n• Employee Director: Qu Ya Nan</p>\n<p>The notice was released in Shanghai on 31 July 2026. No additional agenda items or financial figures were disclosed in the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fudan-Zhangjiang Schedules 14 August 2026 Board Meeting to Review 1H26 Unaudited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFudan-Zhangjiang Schedules 14 August 2026 Board Meeting to Review 1H26 Unaudited Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-31 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (Fudan-Zhangjiang) has announced that its board of directors will convene on 14 August 2026 to review and approve the unaudited interim financial results for the six months ended 30 June 2026.</p>\n<p>The board currently comprises eight members:\n• Executive Directors: Zhao Da Jun (Chairman) and Xue Yan  \n• Non-executive Directors: Zhong Tao and Yu Xiao Yang  \n• Independent Non-executive Directors: Wang Hong Guang, Lam Siu Wing and Xu Pei Long  \n• Employee Director: Qu Ya Nan</p>\n<p>The notice was released in Shanghai on 31 July 2026. No additional agenda items or financial figures were disclosed in the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01349","symbol_name":"复旦张江","start_time":0,"source_url":"","article_id":"1173180583","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173180583","pubTimestamp":1785487606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (Fudan-Zhangjiang) has announced that its board of directors will convene on 14 August 2026 to review and approve the unaudited interim...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01349":"复旦张江"},"translate_title":"复旦张江定于2026年8月14日召开董事会会议，审阅26年上半年未经审计业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01349":1},"content_text":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (Fudan-Zhangjiang) has announced that its board of directors will convene on 14 August 2026 to review and approve the unaudited interim financial results for the six months ended 30 June 2026.\nThe board currently comprises eight members:\n• Executive Directors: Zhao Da Jun (Chairman) and Xue Yan  \n• Non-executive Directors: Zhong Tao and Yu Xiao Yang  \n• Independent Non-executive Directors: Wang Hong Guang, Lam Siu Wing and Xu Pei Long  \n• Employee Director: Qu Ya Nan\nThe notice was released in Shanghai on 31 July 2026. No additional agenda items or financial figures were disclosed in the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}